CD40-Associated TRAF 6 Signaling Is Required for Disease Induction in a Retrovirus-Induced Murine Immunodeficiency by Green, Kathy A et al.
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
2004
CD40-Associated TRAF 6 Signaling Is Required









Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medical Immunology Commons, Medical Microbiology Commons, and the Virology
Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Green, Kathy A.; Ahonen, Cory L.; Cook, W. James; and Green, William R., "CD40-Associated TRAF 6 Signaling Is Required for
Disease Induction in a Retrovirus-Induced Murine Immunodeficiency" (2004). Open Dartmouth: Faculty Open Access Articles. 1307.
https://digitalcommons.dartmouth.edu/facoa/1307
JOURNAL OF VIROLOGY, June 2004, p. 6055–6060 Vol. 78, No. 11
0022-538X/04/$08.000 DOI: 10.1128/JVI.78.11.6055–6060.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
CD40-Associated TRAF 6 Signaling Is Required for Disease Induction
in a Retrovirus-Induced Murine Immunodeficiency
Kathy A. Green,* Cory L. Ahonen, W. James Cook,† and William R. Green
Department of Microbiology and Immunology, Dartmouth Medical School, and
the Norris Cotton Cancer Center, Lebanon, New Hampshire 03756
Received 8 October 2003/Accepted 14 January 2004
LP-BM5 retrovirus-infected C57BL/6 mice develop splenomegaly, lymphadenopathy, hypergammaglobuline-
mia, and immunodeficiency; thus, this disease has been named mouse AIDS. In this syndrome, CD154/CD40
interactions are required for but do not mediate disease by upregulation of CD80 or CD86. We report here that
there is nonetheless a necessity for CD40 signaling competence, specifically an intact tumor necrosis factor
receptor-associated factor 6 (TRAF 6) binding site.
A complex immunodeficiency disease syndrome develops in
certain inbred strains of mice, such as the highly susceptible
C57BL/6 (B6) strain, after infection with the LP-BM5 murine
leukemia retrovirus isolate. Replication-competent ecotropic
(BM5eco), and possibly recombinant mink cell cytopathic fo-
cus-inducing, helper viruses and replication-negative/defective
viruses (BM5def), which serve as the proximal agent causing
the syndrome, are the essential components of this retrovirus
mixture (2, 8, 17, 19, 31). Many features of LP-BM5 induced
disease are similar to those seen in human immunodeficiency
virus-infected individuals. Disease similarities include activa-
tion-related parameters, such as hypergammaglobulinemia
(hyper-Ig), splenomegaly, and lymphadenopathy, and immu-
nodeficiency-related consequences, including severely damp-
ened T- and B-cell responses and increased susceptibility to
disease progression and death when animals were exposed to
environmental pathogens that normally caused limited infec-
tions and the development of terminal B-cell lymphomas (4, 7,
23, 24, 27, 29, 30, 32, 38). Thus, this syndrome has been des-
ignated murine AIDS (MAIDS).
B6 mice infected by LP-BM5 after in vivo depletion of either
CD4 T cells or B cells do not develop MAIDS (7, 38, 39).
Consistent with these cellular requirements, we have previ-
ously demonstrated that CD154/CD40 interactions are neces-
sary for both the induction and progression of MAIDS. By in
vivo treatment with anti-CD154 (CD40 ligand) monoclonal
antibody—either at the initiation of, or 3 to 4 weeks after,
infection—splenomegaly, hyper-Ig, and immunodeficiency
were efficiently inhibited in LP-BM5-infected B6 mice (13, 15).
As confirmation of this requisite molecular interaction for
MAIDS pathogenesis, we and others have also reported that
B6 CD154 (14) and CD40 (14, 40) knockout (k.o.) mice are
essentially resistant to LP-BM5-induced MAIDS. Importantly,
CD40 k.o. mice do express relatively high levels of BM5def
(and especially BM5eco), compared to B6 mice, indicating that
the block to viral pathogenesis is not at the level of initial
infection and virus spread (9, 14, 40). In fact, LP-BM5-infected
CD40 k.o. mice do show some hyper-Ig, at least in terms of
immunoglobulin G (IgG) subclasses and IgE (14, 40).
Regarding the cellular basis for this CD154/CD40 molecular
requirement, we have shown that CD4 T cells and B cells are
necessary for CD154 and CD40 expression, respectively (14).
Although ligation of CD40 on professional antigen-presenting
cells, including B cells, induces a number of overlapping signal
transduction pathways, a central paradigm is that many of the
ultimate functional consequences are determined by the
known downstream upregulation of the costimulatory ligands
for CD28 and CTLA-4: B7-1 (CD80) and B7-2 (CD86) (6, 21,
35–37). However, we have recently reported that the require-
ment for CD40 signaling in MAIDS pathogenesis does not
depend on this classic upregulation of CD80 and/or CD86.
Indeed, B6 CD80/CD86 double-k.o. mice were susceptible to
LP-BM5-induced MAIDS (16). While not absolutely required,
evidence has been reported suggesting that CD80 and/or CD86
may play some role in MAIDS pathogenesis. Thus, soluble
CTLA4Ig or transgenic CTLA4Ig overexpression can partially
inhibit disease induction by a helper-free, related but distinct,
virus preparation, Du5H (10, 11). In addition, other factors
and experimental differences may account for these apparently
conflicting data, as we have discussed in some detail (16).
Here we explore the upstream events more proximal to
CD40 ligation as an alternative approach to define the signal
transduction pathways necessary for MAIDS pathogenesis.
Recent studies have shown that CD154 oligomerization of
CD40 results in recruitment of the cytoplasmic tumor necrosis
factor receptor-associated factors (TRAFs). Specifically, the
TRAF 1, 2, 3, and 5 proteins, as opposed to the TRAF 6
protein, bind to the classic shared 2,3/5 site, as opposed to the
unique 6 site, on the CD40 cytoplasmic tail domain (26, 33, 34).
This binding of these TRAFs to their analogous sites on CD40
leads to activation of Ser and Thr kinases, which then propa-
gate the signal from the CD40 receptor complex to down-
stream mitogen-activated protein kinase and IB kinase cas-
cades.
Our approach here was to utilize a series of mice transgenic
for chimeric hu/mouse CD40 (originally generated by the
NICHD Transgenic Mouse Development Facility, University
of Alabama, Birmingham), which were used after backcrossing
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to CD40 k.o.’s, as detailed in a previous study (1). Available for
study were a CD40 transgenic strain with unaltered (wild-type
[wt]) CD40 sequences and transgenic strains that expressed
selectively mutagenized amino acid sequences in the CD40
cytoplasmic tail to alter the various TRAF binding sites so as to
inhibit TRAF association with CD40. These same “-TRAF
site” constructs were instrumental in a previous in vitro study
that found that cellular responses to CD40 stimulation in a
mouse B-cell line may be TRAF dependent or independent
(28) and in an in vivo setting in which it was determined that
TRAF 6 is necessary for regulation of antibody affinity matu-
ration and the generation of long-lived plasma cells (1). As in
this previous in vivo study, all CD40 transgenic mice used in
the present report were backcrossed to the MAIDS-resistant
CD40 k.o. background (22) so that the only CD40 molecule in
the system was the chimeric transgene-encoded species. Al-
though the levels of transgene expression, as measured by flow
cytometry, varied somewhat, the unaltered wt chimeric trans-
genic strain (which supports LP-BM5-induced MAIDS—see
below) had the lowest expression, while the TRAF 2,3/5, 6
strain had the highest (1).
MAIDS susceptibility of the transgenic strains, in compari-
son to prototypic susceptible B6, was determined after stan-
dard inoculation with LP-BM5. Mice were evaluated for three
or more of the following disease readouts, which we and others
have routinely used, to evaluate disease susceptibility (2, 4, 7,
8, 13–15, 19, 21, 25, 31): spleen size; B- and T-cell immunode-
ficiency as measured by lipopolysaccharide (LPS), concanava-
lin A (ConA), and allospecific cytolytic T-lymphocyte (allo-
CTL) responsiveness and by spleen cell marker phenotypic
changes. Disease parameters were assessed at somewhat ex-
tended times post-LP-BM5 infection, 11 to 14 weeks, to make
sure that we were not misled by merely a shift in disease
kinetics.
To determine if this transgenic system is amenable to inves-
tigate specific CD40 signaling requirements, we first tested the
MAIDS susceptibility of transgenic mice with wt chimeric
CD40 (TRAF 2,3/5, 6), versus chimeric CD40 with both
classic TRAF binding sites disrupted (TRAF 2,3/5, 6). As
shown in Fig. 1, after LP-BM5 infection, wt chimeric CD40
transgenic mice were susceptible to MAIDS-associated spleno-
megaly, with spleens weighing approximately sixfold more than
that for the same strain, uninfected. This level of disease was
similiar to that seen for infected B6 mice. Spleen cells from
infected wt CD40 transgenic mice were also almost completely
nonresponsive to ConA and LPS stimulation, as were cells
from infected B6 mice (Fig. 1), and were unable to generate
allo-CTL in response to H-2d in vitro stimulation (data not
shown).
In contrast, infected CD40 transgenic mice with disrupted
TRAF 2,3/5, and 6 binding sites (TRAF 2,3/5, 6) were
essentially MAIDS insusceptible. In comparison to uninfected
mice, these mice had a similar (not statistically different) av-
erage spleen weight and spleen cell response to LPS, with a
ConA and allo-CTL response that was only somewhat damp-
ened. However, the ConA (Fig. 1) and allo-CTL (data not
shown) responses of TRAF 2,3/5, 6 transgenic mice were
not statistically significantly different (P  0.2993 and P 
0.1911, respectively) compared to those of the control infected
CD40 k.o. strain, which provides the background for all the
transgenic strains. This observed slight “susceptibility” of the
CD40 k.o. background (strain) is consistent with recent reports
by our lab and others that LP-BM5 infection minimally dimin-
ishes mitogen responsiveness in CD40 k.o. mice (14, 40). This
pattern of results was reproduced in two other experiments
involving CD40 wt and TRAF 2,3/5, 6 transgenic strains.
However, in the third experiment, there was no significant
difference for the ConA and allo-CTL responses of LP-BM5-
infected versus uninfected TRAF 2,3/5, 6 transgenic mice,
underscoring that in B6 mice LP-BM5-induced immunodefi-
ciency largely, if not entirely, depends on intact classical CD40
TRAF binding sites. These findings corroborate our earlier
studies, demonstrating the requirement for B-cell-associated
CD40 for MAIDS susceptibility (14) and strongly suggest that
LP-BM5-induced MAIDS is dependent on activation through
CD40, specifically CD40/TRAF signaling.
Determination of viral load by quantitative reverse tran-
scriptase PCR assays (Fig. 1) for both the defective and eco-
tropic helper viral components of LP-BM5, assessed at termi-
nation several weeks postinfection, indicated generally
equivalent high expression for the infected control B6 and wt
chimeric CD40 transgenic mouse groups. For infected TRAF
2,3/5, 6 mice, there was also clear evidence of successful
infection and early spread. However, the defective viral load
for TRAF 2,3/5, 6 mice was perhaps twofold lower than that
of the MAIDS-susceptible strains, while not statistically differ-
ent from that for their background strain, CD40 k.o. Thus, the
requirement of classical CD40 TRAF binding sites for viral
pathogenesis was not mediated by an abolition of infection
(see discussion below).
To determine which specific TRAF binding sites are re-
quired for MAIDS-associated CD40 signaling, we next in-
fected two CD40 transgenic strains bearing sequence muta-
tions that reciprocally alter the binding of TRAF adaptor
molecules to the CD40 cytoplasmic tail (Fig. 2). Thus, either
the classic TRAF 2,3/5 common site or the TRAF 6 site was
mutated (TRAF 2,3/5, 6 or TRAF 2,3/5, 6 transgenic
strains). As previously determined by flow cytometry analysis,
the level of CD40 transgene expression in these two strains is
essentially identical (1). LP-BM5 infection of the TRAF 2,3/
5, 6 transgenic mice resulted in MAIDS by a variety of
criteria: e.g., splenomegaly, with the average spleen weight
approximately threefold higher than that for the uninfected
counterparts. In sharp contrast, spleen weights for the infected
and uninfected TRAF 2,3/5, 6 transgenic strains were sim-
ilar (Fig. 2). Similarly, comparing LP-BM5-infected and unin-
fected mice, it is clear that infection severely impaired the
mitogenic responses to LPS and ConA and inhibited allo-CTL
generation, by the TRAF 2,3/5, 6 transgenic mice, indicat-
ing profound immunodeficiency. On the other hand, these
three immunodeficiency readouts were nearly unchanged in
the infected versus uninfected TRAF 2,3/5, 6 transgenic
mice. Indeed, in one of the two experiments conducted for Fig.
2, TRAF 2,3/5, 6 mice were also available for comparison
(not shown). The transgenic mice with only the TRAF 6 site
mutated versus both TRAF sites mutated behaved very simi-
larly upon infection—there was no evidence that the presence
of an intact TRAF 2,3/5 site by itself led to an increase in
disease susceptibility.
This pattern of results was confirmed by flow cytometry
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analysis for the characteristic conversion to a MAIDS-associ-
ated spleen cell phenotype, as described previously (18, 25).
Infected TRAF 2,3/5, 6 transgenic mice exhibited the
unique changes also seen for infected B6 control mice and at
nearly the same magnitude, i.e., expanded populations of
CD19 CD23 and CD4 Thy1.2 spleen cells (Fig. 3 and
Table 1). In contrast, infected CD40 TRAF 2,3/5, 6 trans-
genic mice showed either essentially no change (CD19
CD23) or only limited increase (CD4 Thy1.2) in these
disease-associated, novel cell subsets.
Collectively, these findings—clear splenomegaly, profound
B- and T-cell immunodeficiency, and substantial spleen cell
phenotypic changes occurring as a consequence of LP-BM5
infection in CD40 TRAF 2,3/5, 6 but not in TRAF 2,3/5,
6 transgenic mice—provide strong evidence that the CD40-
associated TRAF 6 site is required for MAIDS pathogenesis.
The magnitude of various disease parameters was arguably
somewhat less dramatic for infected TRAF 2,3/5, 6 CD40
transgenic mice than for infected prototypic B6 controls, how-
ever, suggesting that there may be CD40-associated aspects
other than the TRAF 6 binding site that also contribute in a
minor way to MAIDS induction.
As shown in the bottom panel of Fig. 2, viral load for the
causative defective genome and the ecotropic helper virus was
assessed by quantitative reverse transcriptase PCR by using
primers previously described (see legend to Fig. 1). All LP-
BM5-infected transgenic mice expressed substantial levels of
both the defective and ecotropic viruses, whereas the levels in
uninfected mice were not detectable. When comparing exper-
imental transgenic strain groups to controls in a given experi-
FIG. 1. wt chimeric hu/mouse CD40 transgenic mice (TRAF 2,3/5, 6) develop MAIDS-associated disease after LP-BM5 infection (3  104
PFU of B ecotropic helper virus). In contrast, infected transgenic mice with CD40 cytoplasmic tail mutations that inhibit TRAF protein binding
to the TRAF 2,3/5, 6 sites (TRAF 2,3/5, 6) do not develop MAIDS. B- or T-cell mitogen responsiveness was determined, respectively, by a 72-h
in vitro stimulation with either 10 g of LPS/ml or 4 g of ConA/ml, followed by a terminal 6-h pulse with [3H]thymidine. These transgenic mice
were all on the CD40 k.o. background. LP-BM5-defective viral load (bottom panel) for spleen tissue was determined by quantitative real-time
reverse transcriptase PCR, as members of our laboratory previously reported (9). Briefly, total RNA was isolated and was DNase I treated. One
microgram of DNA-free RNA was reverse transcribed to cDNA by using random hexamer priming. Reverse transcriptase PCR was performed with
BM5-defective gag (9, 12), ecotropic gag (9), and -actin (9) primers by amplifying resulting cDNA in the presence of SYBR Green stain on an
iCycler iQ instrument (Bio-Rad) by using previously reported temperatures, cycle numbers, and normalization to -actin expression (9). By this
assay, levels of the BM5-defective and BM5 ecotropic viruses were not detectable (ND) in uninfected mice. This experiment is representative of
two additional experiments for the TRAF 2,3/5, 6 transgenic mice, including one in which there was no significant loss of ConA response for
the infected and uninfected mice of this group and one additional experiment for the wt transgenic mice. Mean values and standard deviations were
derived from four mice per group. *, P 	 0.05 by the Student t test, compared to uninfected control mice of the same strain. NS, not significant;
rel. exp., relative expression.
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ment, defective viral load was within about a two- to threefold
difference for those mouse groups that developed MAIDS,
versus those that were insusceptible, following LP-BM5 infec-
tion—e.g., data from Fig. 1. In the case of comparison of the
two transgenic strains with reciprocal mutations in the classical
TRAF binding sites, the differences were somewhat more pro-
nounced (Fig. 2). TRAF 2,3/5, 6 mice had BM5-defective
and ecotropic RNA expression nearly equivalent to that of
control B6 mice, whereas TRAF 2,3/5, 6 mice exhibited
BM5def and BM5eco levels that were only about 20% that of
the two MAIDS-susceptible strains (Fig. 2). However, based
on our experience with virus titration experiments and the
study of several MAIDS-resistant versus -susceptible k.o.
strains (13, 15, 16), this difference does not seem nearly suffi-
cient to explain the lack of classic disease in the TRAF 2,3/5,
6 transgenic strain. Rather, it apparently has to do with the
fact that MAIDS pathogenesis is synonymous with lymphopro-
liferation, which in turn is a major contributor to viral load,
irrespective of free virus spread per se. In addition, comparison
of defective viral loads across experiments (e.g., Fig. 1 and 2)
demonstrated similar two- to fourfold variations in defective
virus expression among mouse groups that did develop
MAIDS. Precise quantitative ecotropic helper virus expression
levels correlate even less well among infected mouse strains
that do, versus those that do not, develop MAIDS—e.g., in-
fected CD40 k.o. mice exhibit relatively high BM5 ecotropic
viral load (Fig. 1), as members of our laboratory previously
reported (9). Thus, it is apparent that the viral loads detected
for the MAIDS-insusceptible CD40-TRAF binding site mutant
strains are likely to be well above any minimum threshold
required for disease. Therefore, the observed differential re-
quirement for TRAF site involvement does not appear to
operate at the levels of virus infectivity or spread.
Recent reports by other investigators have described a
unique role for TRAF 6 in certain CD40-independent and
-dependent signaling contexts: for example, as a signal trans-
ducer for interleukin-1 (IL-1) (5) and as a critical mediator for
CD40-induced IL-6 production, Ig secretion, and upregulation
of CD80 (3, 20). As an extension of the unique role of TRAF
6 in B-cell signaling, we provide strong evidence here that the
FIG. 2. LP-BM5-infected () CD40 transgenic mice with mutated TRAF 2,3/5 and intact TRAF 6 binding sites (TRAF 2,3/5, 6) are MAIDS
susceptible, whereas TRAF 2,3/5, 6 transgenic mice are relatively insusceptible as assessed by readouts for spleen size and B- and T-cell
immunodeficiency. Allo-CTL responses were generated after stimulation with major histocompatibility complex-mismatched irradiated stimulator
cells, followed by a standard 51Cr release assay (13, 14). Mitogen responses and viral load assessment were performed as indicated in the legend
to Fig. 1. Mean values and standard deviations represent a composite of two experiments of four to seven mice per group. *, P	 0.05 by the Student
t test compared to uninfected control mice of the same strain. E:T, effector to target cell.
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TRAF 6 binding site of CD40 is necessary for in vivo patho-
genesis in a physiologically relevant model of murine immu-
nodeficiency that is CD154/CD40 dependent and includes the
development of terminal B-cell lymphomas. Collectively, our
results further suggest that CD154-induced, TRAF 6-medi-
ated, CD40 signaling is required for LP-BM5-initiated
MAIDS. Alternatively, it is possible, for example, that the
mutation strategy for the TRAF 6 binding site resulted instead
in an overall conformational change in the CD40 cytoplasmic
domain such that there was a generalized lack of proper fold-
ing. While possible, in vitro binding studies have confirmed the
selective and undiminished binding of the reciprocal TRAFs to
their respective unmutated binding sites in these constructs
(e.g., reference 34). In addition, numerous functional assays,
both in vitro and in vivo, with mutant CD40-TRAF 2,3/5 or
-TRAF 6 binding sites have demonstrated the continued sig-
naling competence of the unmutated reciprocal TRAF binding
site (e.g., references 1 and 28).
Based on these latter results, our favored interpretation of
the present data is that TRAF 6 is required for signal propa-
gation for MAIDS induction. Assuming that this conclusion is
correct, further studies will obviously be necessary to define the
downstream events that are engaged after TRAF 6-mediated
CD40 signaling in MAIDS. It is also important to point out
that CD40 signaling via the TRAF 6 binding site has to be
viewed in the context of other signaling pathways that are
involved in MAIDS pathogenesis. For example, a recent study
has provided evidence for a role by the CD19/CD21 receptor
complex of B cells and its associated Vav-1 signal-transducing
factor (25). Whether this is an important independent pathway
for MAIDS or whether it relates to the known intersection of
the CD19/CD21 pathway with major histocompatibility com-
plex class II-dependent signaling, which in turn potentiates
B-cell responsiveness to CD40 activation after ligation by
CD154 (see reference 25), remains to be determined. In addi-
tion or as an alternative, it is possible that certain specific
alterations known to occur in CD40-TRAF 2,3/5, TRAF 6
transgenic mice—perhaps most notably the relative lack of
conventional long-lived plasma cells (1)—may hold the key to
explaining the MAIDS insusceptibility of these mice. Similarly,
CD40-TRAF 2,3/5, 6 transgenic strains have a dramatically
reduced ability to produce high-affinity IgG1 antibody re-
sponses in vivo to a model antigen (1).
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